Showing results (21-30 of 179) with videos related to

Sort By:
Pageof 18
Nature Reviews. Cancer|May 3, 2023
Dissecting metastasis using preclinical models and methodsJess D Hebert, Joel W Neal, Monte M Winslow
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinibJonathan W Riess, Seema Nagpal, Joel W Neal, et al.
Clinical Lung Cancer|November 10, 2020
Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung CancerMarian Park, Dora Y Ho, Heather A Wakelee, et al.
Molecular Diagnosis & Therapy|March 31, 2017
Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung CancerHelio A Costa, Joel W Neal, Carlos D Bustamante, et al.
Cancer Treatment and Research Communications|December 17, 2021
Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung CancerJacqueline V Aredo, Heather A Wakelee, Joel W Neal, et al.
Clinical Therapeutics|July 3, 2016
Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted TherapyJody C Chuang, Joseph B Shrager, Heather A Wakelee, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2015
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospectsJody C Chuang, Joel W Neal, Xiao-Min Niu, et al.
Cancer Treatment Reviews|August 29, 2022
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature reviewJeffrey Graham, Arndt Vogel, Ann-Lii Cheng, et al.
Cardiology Clinics|November 17, 2024
Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management StrategiesHoda Sayegh, Alexia Zagouras, Joel W Neal, et al.
Clinical Lung Cancer|July 10, 2024
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung CancerArpeet T Shah, Isabelle Blanchard, Sukhmani K Padda, et al.
Pageof 18